Boston Scientific (BSX) Prelim. Q4 Revenue Misses Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. SPCX
2. SBUX
3. LEVI
4. NVDA
5. GOOGL
6. APLD
7. ORCL
8. USO
9. STZ
10. AAPL

Go back to Boston Scientific (BSX) Prelim. Q4 Revenue Misses Consensus

Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year 2020

January 12, 2021 6:30 AM EST

MARLBOROUGH, Mass., Jan. 12, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE:  BSX) generated net sales, based upon preliminary unaudited financial information, of approximately $2.71 billion during the fourth quarter of 2020. This represents a decline of approximately (6.8) percent on a reported basis, approximately (8.3) percent on an operational1 basis and approximately (8.0) percent on an organic2 basis, all compared to the prior year period. Included within organic results is a negative 370 basis point impact associated with the conversion of U.S. WATCHMAN customers to a consignment inventory model and transition to the next-generation WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device.

... More